CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 12, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
TransCode Therapeutics Open Letter to Shareholders
November 12, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
Open Letter to Shareholders
Peptide Therapeutics Market Size to Surpass USD 76.11 Billion by 2033 | Straits Research
November 11, 2024 10:10 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different...
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
November 11, 2024 08:00 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
EvolveImmune Therapeutics Presents New Preclinical and Translational Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 11, 2024 07:00 ET
|
EvolveImmune
Poster Presentations Spotlight Differentiated Therapeutic Profile and Precision Therapeutic Strategy for Lead Development Candidate EVOLVE104 as Program Advances Toward Clinic for Solid Tumors EVOLVE...
Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition in murine models of breast, colorectal, and prostate cancers
November 08, 2024 14:51 ET
|
Io Therapeutics, Inc.
Io Therapeutics, Inc., presents data on IRX5010 showing inhibition of tumor infiltrating T-cells and myeloid derived suppressor cells in multiple cancers
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
November 07, 2024 08:30 ET
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer
November 07, 2024 07:00 ET
|
SynOx Therapeutics Limited
Additions of Elyse Seltzer, M.D., as CMO and Robert Francomano as CCO Strengthen Company’s Presence in the U.S. Seasoned Team to Drive Forward Pivotal Phase 3 Trial of Emactuzumab in Patients...
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
November 06, 2024 16:02 ET
|
Revolution Medicines, Inc.
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a...
[Latest] Global Cancer Cell Analysis Market Size/Share Worth USD 23.31 Billion by 2033 at a 8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
November 06, 2024 13:00 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Cell Analysis Market Size, Trends and Insights By Application (Cancer...